Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECLARE: Dapagliflozin Effect on Cardiovascular Events
2013-000239-28Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and cardiac morbidity comparing dapagliflozin with placebo (2 arms). Primary endpoints: Composite of cardiovascular death, myocardial infarction, or ischemic stroke and Composite of hospitalization for heart failure or cardiovascular death. Started Apr 2013; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on 2013-000239-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000239-28.